Hyphens Pharma International: Navigating Challenges with Strategic Focus March 17, 2026
Company Overview
Hyphens Pharma International is a pharmaceutical company operating across ASEAN markets with a diversified portfolio spanning specialty pharmaceuticals, proprietary brands, and medical hypermart operations. The company has been expanding its reach across Southeast Asia whilst making strategic inroads into European markets.
Financial Performance and Strategic Refresh
Hyphens Pharma delivered FY25 results broadly in line with expectations, with revenue and adjusted profit after tax and minority interests achieving 99% and 97% of forecasts respectively. The second half of FY25 demonstrated resilience, with adjusted PATMI rebounding 27% year-on-year to S$5.94 million, driven by the discontinuation of low-margin products and enhanced cost controls.
However, the overall financial picture was mixed. Revenue declined 8% year-on-year to S$97.8 million in 2H25, primarily due to a 23% drop in Vietnamese operations. The company faced multiple headwinds in Vietnam, including elevated Sterimar, a natural, drug-free seawater nasal spray, inventory levels, deprioritisation of contrast media products, currency weakness, and strategic product discontinuations.
Operational Challenges and Strategic Positives
The company encountered significant operational hurdles, particularly in Vietnam, which necessitated a strategic refresh. We believe the company faced challenges in passing through higher-priced Euro specialty products to customers, prompting a realignment towards better-margin products. It allowed gross profit margins to improve substantially, jumping 5.7 percentage points year-on-year to 41.9% in 2H25, demonstrating the effectiveness of the margin enhancement strategy.
The positive momentum was partially offset by increased provisions totalling several million dollars, including inventory write-offs of S$1 million, impairment of receivables worth S$0.6 million, and foreign exchange translation losses of S$0.8 million, all largely related to Vietnamese operations.
Growth Prospects and Valuation
Phillip Securities Research maintains a BUY recommendation with a target price of S$0.40, raising FY26 PATMI estimates by 10% to S$12.2 million based on improved gross margin projections. The company achieved a significant milestone in January with an out-licensing agreement for Cerapro MED, an atopic dermatitis treatment, across six European countries. Additionally, Winlevi anti-acne products are gaining traction in Singapore and Malaysia.
Trading at an attractive 8x price-to-earnings ratio with net cash of S$26.8 million representing 27% of market capitalisation, the company appears well-positioned for recovery as Vietnamese operations stabilises and growth drivers including medical aesthetics and e-pharmacy initiatives gain momentum.
Frequently Asked Questions
Q: What was Hyphens Pharma’s financial performance in FY25?
A: FY25 revenue and adjusted PATMI were within expectations at 99% and 97% of forecasts respectively. 2H25 adjusted PATMI rebounded 27% year-on-year to S$5.94 million, though headline earnings declined due to FX translation losses and extraordinary provisions.
Q: Why did revenue decline in 2H25?
A: Revenue declined 8% year-on-year to S$97.8 million in 2H25, primarily driven by a 23% drop in Vietnamese operations due to elevated inventory, currency weakness, and strategic product discontinuations.
Q: What challenges did the company face in Vietnam?
A: Vietnam operations encountered elevated Sterimar inventory, deprioritisation of contrast media, weak currency conditions, discontinuation of several products, and difficulties in passing through higher-priced Euro specialty products to customers.
Q: How did gross margins perform?
A: Gross profit margins improved significantly, jumping 5.7 percentage points year-on-year to 41.9% in 2H25, helping gross profit grow despite declining revenue through discontinuation of low-margin products like Physiolac infant formula.
Q: What is Phillip Securities Research’s recommendation?
A: Phillip Securities Research maintains a BUY recommendation with a target price of S$0.40, raising FY26 PATMI estimates by 10% to S$12.2 million based on higher gross margin estimates.
Q: What are the key growth drivers for 2026?
A: Expected growth drivers for 2026 include Winlevi anti-acne products, medical aesthetics, and Wellaway e-pharmacy operations, alongside the strategic refresh of Vietnam’s product portfolio.
Q: What significant milestone did the company achieve?
A: In January, Hyphens reached a milestone with an out-licensing agreement for Cerapro MED, an atopic dermatitis treatment, into six European countries, marking successful expansion into European markets.
Q: What is the company’s current valuation and financial position?
A: Hyphens trades at an attractive 8x price-to-earnings ratio with net cash of S$26.8 million, representing 27% of its market capitalisation, providing a strong financial foundation for future growth.
This article has been auto-generated using AI tools. It is based on a report by a Phillip Securities Research analyst.
Disclaimer
These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products.
Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance.
Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries.
The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries.
Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.
About the author
Paul Chew
Paul has more than 25 years of experience as a fund manager and sell-side analyst. He currently covers sectors such as healthcare, electronics, telecommunications, conglomerates, small caps, and strategy.
He graduated from Monash University and has completed both his Chartered Financial Analyst and Australian CPA programme.
SATS Upgraded to Buy on Strong Cargo Performance 
City Developments Limited Delivers Record Performance Through Strategic Asset Recycling 
ComfortDelGro Corp Faces Accelerating Taxi Fleet Decline Despite Stable Overall Performance 
Singapore REITs in 2026: A Year for Selective Optimism 
